日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Saccharomyces cerevisiae Probable metabolite transport protein GIT1 (GIT1), partial CSB-YP335112SVG
CSB-EP335112SVG
CSB-BP335112SVG
CSB-MP335112SVG
CSB-EP335112SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Putative uncharacterized protein YCR025C (YCR025C) CSB-YP335113SVG
CSB-EP335113SVG
CSB-BP335113SVG
CSB-MP335113SVG
CSB-EP335113SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Forkhead transcription factor HCM1 (HCM1), partial CSB-YP335114SVG
CSB-EP335114SVG
CSB-BP335114SVG
CSB-MP335114SVG
CSB-EP335114SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Probable ATP-dependent permease (ADP1), partial CSB-YP335115SVG
CSB-EP335115SVG
CSB-BP335115SVG
CSB-MP335115SVG
CSB-EP335115SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Transposon Ty2-C Gag polyprotein (TY2A-C) CSB-YP335116SVG
CSB-EP335116SVG
CSB-BP335116SVG
CSB-MP335116SVG
CSB-EP335116SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Queuine tRNA-ribosyltransferase-like protein CSB-YP335117PLO
CSB-EP335117PLO
CSB-BP335117PLO
CSB-MP335117PLO
CSB-EP335117PLO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Emericella nidulans Quinate dehydrogenase (qutB) CSB-YP335118EKF
CSB-EP335118EKF
CSB-BP335118EKF
CSB-MP335118EKF
CSB-EP335118EKF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Mycobacterium phage FRAT1 Integrase (int) CSB-YP335119MLB
CSB-EP335119MLB
CSB-BP335119MLB
CSB-MP335119MLB
CSB-EP335119MLB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Drosophila melanogaster 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase classes I and II (Plc21C), partial CSB-YP335120DLU
CSB-EP335120DLU
CSB-BP335120DLU
CSB-MP335120DLU
CSB-EP335120DLU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Zea mays Glutamine synthetase, chloroplastic (GLN2) CSB-YP335121ZAX
CSB-EP335121ZAX
CSB-BP335121ZAX
CSB-MP335121ZAX
CSB-EP335121ZAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pisum sativum Histone H2A.1 CSB-YP335122EWE
CSB-EP335122EWE
CSB-BP335122EWE
CSB-MP335122EWE
CSB-EP335122EWE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Enterobacteria phage P2 Presumed capsid-scaffolding protein (O) CSB-YP335123EDE
CSB-EP335123EDE
CSB-BP335123EDE
CSB-MP335123EDE
CSB-EP335123EDE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Minor capsid protein L2 (L2) CSB-YP335124HNA
CSB-EP335124HNA
CSB-BP335124HNA
CSB-MP335124HNA
CSB-EP335124HNA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pseudechis australis Short neurotoxin 1 CSB-YP335125EZS
CSB-EP335125EZS
CSB-BP335125EZS
CSB-MP335125EZS
CSB-EP335125EZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Proline utilization trans-activator (PUT3), partial CSB-YP335126SVG
CSB-EP335126SVG
CSB-BP335126SVG
CSB-MP335126SVG
CSB-EP335126SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Placobdella ornata Ornatin-D CSB-YP335127PLA
CSB-EP335127PLA
CSB-BP335127PLA
CSB-MP335127PLA
CSB-EP335127PLA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli tRNA modification GTPase MnmE (mnmE) CSB-YP335128ENV
CSB-EP335128ENV
CSB-BP335128ENV
CSB-MP335128ENV
CSB-EP335128ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Protein visC (visC) CSB-YP335129ENV
CSB-EP335129ENV
CSB-BP335129ENV
CSB-MP335129ENV
CSB-EP335129ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Agrobacterium tumefaciens Multiple sugar-binding periplasmic receptor ChvE (chvE) CSB-YP335130AYS
CSB-EP335130AYS
CSB-BP335130AYS
CSB-MP335130AYS
CSB-EP335130AYS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Putative uncharacterized protein YCL021W (YCL021W) CSB-YP335131SVG
CSB-EP335131SVG
CSB-BP335131SVG
CSB-MP335131SVG
CSB-EP335131SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×